InterCure Ltd.

Equities

INCR

IL0011063760

Healthcare Facilities & Services

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:05 2024-05-01 am EDT			5-day change	1st Jan Change
1,150 ^ILa	+14.09%		+15.89%	+148.33%

Apr. 01	InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023	CI
Mar. 22	InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months	CI

InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023

April 01, 2024 at 09:02 am EDT

InterCure Ltd. provided earnings guidance for the second half and full year of 2023. For the second half, the company is estimated revenue at ILS 140 million.

For the year, the company's Annual revenue is estimated at ILS 351 million.

Latest news about InterCure Ltd.

InterCure Ltd. Provides Earnings Guidance for the Second Half and Full Year of 2023	Apr. 01	CI
InterCure Ltd. Expects to Launch Its First Products in Germany in the Coming Months	Mar. 22	CI
InterCure Ltd. Announces Resignation of Rami Levy as Chief of Operations	Feb. 13	CI
InterCure Ltd. entered into a share purchase agreement to acquire Leon Pharm Ltd for ILS 8.3 million.	Jan. 30	CI
InterCure Ltd.(TASE:INCR) dropped from S&P Global BMI Index	23-09-18	CI
InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Intercure to Delist Its Shares From the Toronto Stock Exchange	23-07-10	MT
InterCure Provides Update About Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger	23-06-12	MT
Transcript : InterCure Ltd., 2022 Earnings Call, Apr 04, 2023	23-04-04
InterCure Ltd. entered into an agreement to acquire 51% stake in Orni Pharmacy Ltd.	22-11-15	CI
InterCure to Launch Trading on Nasdaq Wednesday	21-09-01	MT
InterCure Ltd. Announces Earnings Results for the Second Quarter Ended June 30, 2021	21-08-16	CI
InterCure Provided Update on Its NASDAQ Listing	21-07-12	MT
InterCure Ltd signed a Letter of Intent to acquire Cann Pharmaceutical Ltd. for $35 million.	21-04-04	CI
InterCure : Israel's Canndoc signs cannabis import-export deal with Tilray	20-01-02	RE
Regenera Pharma Ltd. announced that it expects to receive funding from InterCure Ltd. and other investors	16-12-17	CI
InterCure Ltd. announced that it has received ILS 1.5 million in funding	16-12-03	CI
InterCure Ltd. announced that it expects to receive ILS 1.5 million in funding	16-11-27	CI
InterCure Ltd. completed the acquisition of additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments Ltd.	16-09-26	CI
InterCure Ltd. signed an agreement to acquire additional 7.43% stake in Regenera Pharma Ltd. from Bamot Investments Ltd. for ILS 3 million.	16-09-10	CI
Novellusdx Ltd. announced that it has received $12.5 million in funding from Pontifax Ltd., InterCure Ltd., OrbiMed Advisors, L.L.C.	16-06-21	CI

Chart InterCure Ltd.

Duration

Period

More charts

Company Profile

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Sector

Healthcare Facilities & Services

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Sector Medical Farming

	1st Jan change	Capi.
INTERCURE LTD.	+148.33%	140M
AYR WELLNESS INC.	+46.09%	284M
ASCEND WELLNESS HOLDINGS, INC.	+30.93%	270M
ORGANIGRAM HOLDINGS INC.	+53.49%	198M
THE CANNABIST COMPANY HOLDINGS INC.	-28.99%	146M
JUSHI HOLDINGS INC.	+56.76%	142M
IANTHUS CAPITAL HOLDINGS, INC.	-28.57%	120M
4FRONT VENTURES CORP.	+3.85%	89.69M
BAKHU HOLDINGS, CORP.	+150.00%	75.33M
GOLD FLORA CORPORATION	+11.25%	68.6M

Medical Farming